Bovine colostrum supplementation does not affect nutrient absorptive capacity in healthy young men

Milk diets influence doxorubicin-induced intestinal toxicity in piglets

Chemotherapy-induced gastrointestinal (GI) toxicity is a common adverse effect of cancer treatment. We used preweaned piglets as models to test our hypothesis that the immunomodulatory and GI trophic effects of bovine colostrum would reduce the severity of GI complications associated with doxorubicin (DOX) treatment. Five-day-old pigs were administered DOX (1 × 100 mg/m(2)) or an equivalent volume of saline (SAL) and either fed formula (DOX-Form, n = 9, or SAL-Form, n = 7) or bovine colostrum (DOX-Colos, n = 9, or SAL-Colos, n = 7). Pigs were euthanized 5 days after initiation of chemotherapy to assess markers of small intestinal function and inflammation. All DOX-treated animals developed diarrhea, growth deficits, and leukopenia. However, the intestines of DOX-Colos pigs had lower intestinal permeability, longer intestinal villi with higher activities of brush border enzymes, and lower tissue IL-8 levels compared with DOX-Form (all P < 0.05). DOX-Form pigs, but not DOX-Colos pigs, had significantly higher plasma C-reactive protein, compared with SAL-Form. Plasma citrulline was not affected by DOX treatment or diet. Thus a single dose of DOX induces intestinal toxicity in preweaned pigs and may lead to a systemic inflammatory response. The toxicity is affected by type of enteral nutrition with more pronounced GI toxicity when formula is fed compared with bovine colostrum. The results indicate that bovine colostrum may be a beneficial supplementary diet for children subjected to chemotherapy and subsequent intestinal toxicity.

Bovine colostrum, training status, and gastrointestinal permeability during exercise in the heat: a placebo-controlled double-blind study

Heat stress can increase gastrointestinal permeability, allowing ingress of gram-negative bacterial fragments and thus potentially inflammation and ultimately endotoxemia. Permeability may rise with intense exercise, yet some data indicate that endotoxemia may be mitigated with bovine colostrum supplementation. Using a double-blind, randomised, placebo-controlled crossover study, we tested whether bovine colostrum (COL; 1.7 g·kg(-1)·day(-1) for 7 days) would attenuate physiological strain and aid exercise capacity in the heat, especially in untrained individuals. Seven trained men (T; peak oxygen uptake 64 ± 4 mL·kg(-1)·min(-1)) and 8 untrained men (UT, peak oxygen uptake 46 ± 4 mL·kg(-1)·min(-1)) exercised for 90 min in 30 °C (50 % relative humidity) after COL or placebo (corn flour). Exercise consisted of 15-min cycling at 50 % heart rate reserve (HRR) before and after 60 min of running (30 min at 80 % HRR then 30-min distance trial). Heart rate, blood pressure (Finometer), esophageal, and skin temperatures were recorded continuously. Gastrointestinal permeability was assessed from urine (double-sugar model, using high-performance liquid chromatography) and blood (intestinal fatty acid-binding protein, I-FABP). The T group ran ∼2.4 km (35%) further than the UT group in the distance trial, and I-FABP increased more in the T group than in the UT group, but physiological and performance outcomes were unaffected by colostrum supplementation, irrespective of fitness. Circulating pro- and anti-inflammatory cytokine concentrations were higher following exercise, but were not modulated by fitness or COL. Despite substantial thermal and cardiovascular strain incurred in environmental conditions in which exertional endotoxemia may occur, bovine colostrum supplementation had no observable benefit on the physiology or performance of either highly trained endurance athletes or untrained individuals.

Bovine colostrum in the management of nonorganic failure to thrive: a randomized clinical trial

OBJECTIVE

The objective of the study was to evaluate the clinical efficacy of oral bovine colostrum in the management of nonorganic failure to thrive (FTT).

MATERIALS AND METHODS

In a randomized clinical trial, 120 children (1-10 years of age) of either sex with mild or moderate nonorganic FTT were divided into 2 groups. Both groups were matched with regard to age, sex, weight, and height. One group (control) received routine treatments for FTT and the other group (case), besides routine treatments, received supplementary bovine colostrum at the dose of 40 mg . kg . day for a 3-month period. Following the initial visit, subsequent visits were completed following 1, 2, and 3 months of supplementation. For quantitative measurements, Waterlow I (height for age) and Gomez (weight for age) indices were used.

RESULTS

The mean value of Gomez index in the case group (81.72) was significantly higher than the control group (77.12) at the end of the third month of supplementation (P = 0.003). Such a difference was not reported based on Waterlow I index between the case and control groups (92.91 vs 91.71; P = 0.094). According to Gomez index 12 patients (20%) who received colostrum became healthy at the end of the third month, which was significantly higher than the control group (2 cases, 3.3%); P = 0.006.

CONCLUSIONS

Bovine colostrum supplementation for a 3-month period is a useful method without any side effects, in addition to known medical and psychological treatments, to increase the weight of children with nonorganic FTT.

Bovine colostrum supplementation during running training increases intestinal permeability

Endurance exercise training can increase intestinal permeability which may contribute to the development of gastrointestinal symptoms in some athletes. Bovine colostrum (BC) supplementation reduces intestinal permeability induced by non-steroidal anti-inflammatory drugs. This study aimed to determine whether BC could also reduce intestinal permeability induced by endurance exercise. Thirty healthy adult males (25.0 ± 4.7 yr; mean ± SD) completed eight weeks of running three times per week for 45 minutes at their lactate threshold while consuming 60 g/day of BC, whey protein (WP) or control (CON). Intestinal permeability was assessed at baseline and after eight weeks by measuring the ratio of urinary lactulose (L) and rhamnose (R) excretion. After eight weeks the L/R ratio increased significantly more in volunteers consuming BC (251 ± 140%) compared with WP (21 ± 35%, P < 0.05) and CON (−7 ± 13%, P < 0.02). The increase in intestinal permeability with BC may have been due to BC inducing greater leakiness of tight junctions between enterocytes or by increasing macromolecular transport as it does in neonatal gut. Further research should investigate the potential for BC to increase intestinal macromolecular transport in adults.